The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Alyamany R, Alnughmush A, Almutlaq M, Alyamany M, Alfayez M

Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management.

Frontiers in oncology. 2024;14:1345492

Litvin R, Dasgupta M, Saad Eldin M, Shah M, Fakhran S

Azacitidine-Induced Pneumonitis in a Patient With Acute Myeloid Leukemia and Hyperleukocytosis.

Cureus. 2022;14(7):e26758

Molina M, Yellapragada S, Mims M, Rahman E, Rivero G

Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia.

Case reports in hematology. 2015;2015:357461

Verriere B, Ferreira V, Denis E, Zahreddine K, Deletie E, Quinsat D, Re D

Azacitidine-Induced Interstitial Pneumonitis.

American journal of therapeutics. 2016;23(5):e1205-8

Hayashi M, Takayasu H, Tada M, Yamazaki Y, Tateno H, Tazawa S, Wakabayashi A, Iwasaki T, Tsuchiya Y, Yamashita J, Takeda N, Tomita S, Mori H, Kokubu F

Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.

Internal medicine (Tokyo, Japan). 2012;51(17):2411-5

Hueser CN, Patel AJ

Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.

Pharmacotherapy. 2007;27(12):1759-62